US2012142734A1PendingUtilityA1

Methods for treating tumors with thalidomide

46
Assignee: D AMATO ROBERTPriority: Mar 1, 1993Filed: Feb 14, 2012Published: Jun 7, 2012
Est. expiryMar 1, 2013(expired)· nominal 20-yr term from priority
Inventors:Robert D'Amato
A61P 9/00A61P 35/00A61K 31/40
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.

Claims

exact text as granted — not AI-modified
1 - 24 . (canceled) 
     
     
         25 . A method for treating a tumor in a patient having a tumor comprising orally administering between approximately 0.5 and approximately 50 mg/kg/day of thalidomide to said patient. 
     
     
         26 . The method of  claim 25 , wherein the tumor is a blood-born tumor. 
     
     
         27 . The method of  claim 26 , wherein the tumor is multiple myeloma. 
     
     
         28 . The method of  claim 25 , wherein the tumor is cancerous. 
     
     
         29 . The method of  claim 25 , wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day. 
     
     
         30 . The method of  claim 25 , wherein undesired angiogenesis occurs in the tumor. 
     
     
         31 . The method of  claim 25 , wherein said thalidomide is administered in a capsule. 
     
     
         32 . The method of  claim 26 , wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day. 
     
     
         33 . The method of  claim 26 , wherein undesired angiogenesis occurs in the tumor. 
     
     
         34 . The method of  claim 26 , wherein said thalidomide is administered in a capsule. 
     
     
         35 . The method of  claim 27 , wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day. 
     
     
         36 . The method of  claim 27 , wherein undesired angiogenesis occurs in the tumor. 
     
     
         37 . The method of  claim 27 , wherein said thalidomide is administered in a capsule.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.